Share Article

Boston Scientific has Entered into a Definitive Agreement to Acquire Augmenix Inc.

Request More Information

We are pleased to announce that Boston Scientific (NYSE: BSX) has entered into a definitive agreement to acquire Augmenix Inc. More details on the agreement can be found here.

The Augmenix team greatly appreciates and recognizes all of the many physicians, physicists and associated healthcare professionals who have been the pioneers in treating their patients with our innovative hydrogel technologies. From the initial clinical trials to early commercial use, our physician partners have consistently practiced sound medicine and good science, while always putting the patient first.  These world-class leaders have contributed much in making hydrogel spacing an important technology advancement in radiation oncology.

While this definitive agreement represents a significant milestone for Augmenix, it’s just the beginning of expanding the benefits of spacing to an even greater number of cancer patients around the world. We are proud to have a partner such as Boston Scientific help us undertake this global journey.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit and connect on Twitter and Facebook.